Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
September 10 2021 - 8:00AM
Business Wire
- ePoster presentation highlights findings from
a new post-hoc analysis evaluating efficacy and safety of the RHA®
Collection -
- Supports Revance’s commitment to ensuring
safety and efficacy of aesthetic product portfolio among diverse
patient populations -
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company focused on innovative aesthetic and therapeutic offerings,
today announced that its data will be featured during the 2021
Virtual Skin of Color Update meeting, taking place September 10-12,
2021. The presentation highlights findings from a new post-hoc
subgroup analysis evaluating the effectiveness and safety of the
RHA® Collection of dermal fillers for the correction of
moderate-to-severe nasolabial folds (NLFs) in patients with darker
skin color.
“The RHA® Collection is the latest advancement in hyaluronic
acid filler technology and we’re looking forward to sharing new
data at the 2021 Virtual Skin of Color Update,” said Roman Rubio,
Senior Vice President of Clinical Development at Revance. “The data
presented highlights the safety and effectiveness of the RHA®
Collection in treating moderate-to-severe nasolabial folds in an
increasingly prominent patient population that is often
underrepresented in clinical studies within aesthetic medicine. The
study supports the innovation of Revance’s growing aesthetics
portfolio while underscoring our commitment to proper treatment for
diverse ethnicities and medical education for various skin
types.”
The ePoster presentation will be available on-demand online via
the Skin of Color Update website at skinofcolorupdate.com.
ePoster Presentation:
- Title: Effectiveness and safety of Resilient Hyaluronic
Acid (RHA®) dermal fillers for the correction of moderate-to-severe
nasolabial folds in subjects with darker skin color: post-hoc
subgroup analyses of US pivotal clinical data
-
Authors and Affiliations: Jay Mashburn, Kristie Kooken,
Yan Liu, Revance Therapeutics, Inc., Nashville, TN
About Revance Therapeutics
Revance Therapeutics, Inc. is a biotechnology company focused on
innovative aesthetic and therapeutic offerings, including its
next-generation neuromodulator product, DaxibotulinumtoxinA for
Injection. DaxibotulinumtoxinA for Injection combines a proprietary
stabilizing peptide excipient with a highly purified botulinum
toxin that does not contain human or animal-based components.
Revance has successfully completed a Phase 3 program for
DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is
pursuing U.S. regulatory approval in 2020. Revance is also
evaluating DaxibotulinumtoxinA for Injection in the full upper
face, including glabellar lines, forehead lines and crow’s feet, as
well as in three therapeutic indications - cervical dystonia, adult
upper limb spasticity and plantar fasciitis. To accompany
DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio
of premium products and services for U.S. aesthetics practices,
including the exclusive U.S. distribution rights to the RHA®
Collection of dermal fillers, the first and only range of
FDA-approved fillers for correction of dynamic facial wrinkles and
folds, and the HintMD fintech platform, which includes integrated
smart payment, subscription and loyalty digital services. Revance
has also partnered with Mylan N.V. to develop a biosimilar to
BOTOX®, which would compete in the existing short-acting
neuromodulator marketplace. Revance is dedicated to making a
difference by transforming patient experiences. For more
information or to join our team visit us at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
Forward Looking Statements
Any statements in this press release that are not statements of
historical fact, including statements related to development of a
biosimilar to BOTOX®; the potential benefits of the RHA® Collection
of dermal fillers; statements about our strategy, plans and
prospects, including patient population; the growth of our
aesthetics portfolio; and the market opportunity for the RHA®
Collection of dermal fillers and our product candidates, constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. You should not rely
upon forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
the future results, levels of activity, performance, events,
circumstances or achievements reflected in the forward-looking
statements will ever be achieved or occur.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties relate, but
are not limited to: the results, timing, costs, and completion of
our research and development activities and regulatory approvals,
including the continuing delay in the FDA’s approval of the BLA for
DaxibotulinumtoxinA for Injection for the treatment of glabellar
lines, including as a result of observations made by the FDA during
the site inspection or other reasons; the impact of the COVID-19
pandemic on our manufacturing operations, supply chain, end user
demand for our products, commercialization efforts, business
operations, clinical trials and other aspects of our business and
on the market; our ability to manufacture supplies for our product
candidates and to acquire supplies of the RHA® Collection of dermal
fillers; the uncertain clinical development process; the risk that
clinical trials may not have an effective design or generate
positive results; the applicability of clinical study results to
actual outcomes; the rate and degree of economic benefit, the
safety, efficacy, commercial acceptance and the market,
competition, size and growth potential of the RHA® Collection of
dermal fillers and our dug product candidates, if approved; our
ability to continue to successfully commercialize the RHA®
Collection of dermal fillers and fintech platform and our ability
to successfully commercialize DaxibotulinumtoxinA for Injection, if
approved, and the timing and cost of commercialization activities;
our ability to expand sales and marketing capabilities; the status
of commercial collaborations; our ability to obtain funding for our
operations; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates;
our financial performance, including future revenue, expenses and
capital requirements; and other risks. Detailed information
regarding factors that may cause actual results to differ
materially from the results expressed or implied by statements in
this press release may be found in our periodic filings with the
Securities and Exchange Commission (SEC), including factors
described in the section entitled "Risks Factors" on our Form 10-K
filed with the SEC on February 25, 2021 and including, without
limitation, our Form 10-Q for the quarter ended June 30, 2021,
filed with the SEC on August 5, 2021. The forward-looking
statements in this press release speak only as of the date hereof.
We disclaim any obligation to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210910005255/en/
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com
Investors Revance Therapeutics, Inc.: Jessica Serra,
626-589-1007 Jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Oct 2023 to Oct 2024